The Effect of Quercetin in Sarcoidosis

Sarcoidosis Clinical Trial

Official title:

The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00402623
• Other study ID #: MEC 05.142.5
• Status: Completed
• Phase: N/A
• First received: November 20, 2006
• Last updated: February 22, 2017
• Start date: January 2006
• Est. completion date: January 2006

Study information

• Verified date: February 2008
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.

Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 2006
• Est. primary completion date: January 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis

• no smoking

• no treatment

Exclusion Criteria:

• clinical diagnosis (and treatment) of other diseases

• symptoms of sarcoidosis in other organs besides the lung

• use of food supplements or vitamins

Related Conditions & MeSH terms

• Sarcoidosis

Intervention

Dietary Supplement:
• quercetin
1000 mg quercetin within 24 hours

Other:
• placebo

Locations

Country	Name	City	State
Netherlands	Maastricht University	Maastricht

Sponsors (2)

Lead Sponsor	Collaborator
Maastricht University Medical Center	ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	antioxidant status after 24 hours		24 hours
Primary	inflammatory status after 24 hours		24 hours
Secondary	plasma quercetin concentration after 24 hours		24 hours
Secondary	plasma malondialdehyde (MDA) levels after 24 hours		24 hours